The potential and promise of IL-15 in immuno-oncogenic therapies

Immunology Letters

Volumn 190, Issue , 2017, Pages 159-168

  Robinson, Tanya O ^a   Schluns, Kimberly S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALT 803; Clinical trials; Cytotoxic lymphocytes; IL 15; Immunotherapy; Soluble IL 15 complexes

Indexed keywords

ALEMTUZUMAB; ALT 803; BCG VACCINE; CYCLOPHOSPHAMIDE; ELOTUZUMAB; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYBRID PROTEIN; INTERLEUKIN 15; INTERLEUKIN 15 DERIVATIVE; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; MELPHALAN; NIVOLUMAB; PACLITAXEL; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; UNCLASSIFIED DRUG; INTERLEUKIN 15 RECEPTOR;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER MODEL; CAPILLARY LEAK SYNDROME; CARCINOMA; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ARRHYTHMIA; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MELANOMA; MERKEL CELL CARCINOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUROBLASTOMA; NON MUSCLE INVASIVE BLADDER CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SOLID MALIGNANT NEOPLASM; T CELL LEUKEMIA; UTERINE TUBE CARCINOMA; ANIMAL; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; PROTEIN STABILITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; KILLER CELLS, NATURAL; NEOPLASMS; PROTEIN STABILITY; RECEPTORS, INTERLEUKIN-15;

EID: 85028027225     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2017.08.010     Document Type: Review

References (91)

1. Rosenberg, S.A., Yang, J.C., White, D.E., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228 (1998), 307–319.
2. Yang, J.C., Sherry, R.M., Steinberg, S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21 (2003), 3127–3132.
3. Fyfe, G., Fisher, R.I., Rosenberg, S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13 (1995), 688–696.
4. Smith, F.O., Downey, S.G., Klapper, J.A., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14 (2008), 5610–5618.
5. Dudley, M.E., Wunderlich, J.R., Yang, J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23 (2005), 2346–2357.
6. Dudley, M.E., Yang, J.C., Sherry, R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26 (2008), 5233–5239.
7. Cheever, M.A., Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222 (2008), 357–368.
8. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
9. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
10. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
11. Ali, A.K., Nandagopal, N., Lee, S.H., IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells. Front. Immunol., 6, 2015, 355-.
12. Kennedy, M.K., Glaccum, M., Brown, S.N., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191 (2000), 771–780.
13. Lodolce, J.P., Boone, D.L., Chai, S., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9 (1998), 669–676.
14. Stonier, S.W., Ma, L.J., Castillo, E.F., et al. Dendritic cells drive memory CD8 T cell homeostasis via IL-15 trans-presentation. Blood, 2008, 4546–4554.
15. Mortier, E., Advincula, R., Kim, L., et al. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8(+) T cell subsets. Immunity 31 (2009), 811–822.
16. Anthony, S.M., Howard, M.E., Hailemichael, Y., et al. Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. PLoS One, 10, 2015, e0120274-.
17. Anthony, S.M., Rivas, S.C., Colpitts, S.L., et al. Inflammatory signals regulate IL-15 in response to lymphodepletion. J. Immunol. 196 (2016), 4544–4552.
18. Rubinstein, M.P., Kovar, M., Purton, J.F., et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 9166–9171.
19. Stoklasek, T.A., Schluns, K.S., Lefrancois, L., Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177 (2006), 6072–6080.
20. Bergamaschi, C., Rosati, M., Jalah, R., et al. Intracellular interaction of interleukin-15 with its receptor {alpha} during production leads to mutual stabilization and increased bioactivity. J. Biol. Chem. 283 (2008), 4189–4199.
21. Schluns, K.S., Klonowski, K.D., Lefrancois, L., Transregulation of memory CD8 T-cell proliferation by IL-15R alpha(+) bone marrow-derived cells. Blood 103 (2004), 988–994.
22. Burkett, P.R., Koka, R., Chien, M., et al. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4724–4729.
23. Koka, R., Burkett, P.R., Chien, M., et al. Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J. Exp. Med. 197 (2003), 977–984.
24. Burkett, P.R., Koka, R., Chien, M., et al. Coordinate expression and trans presentation of interleukin (IL)-15R{alpha} and IL-15 supports natural killer cell and memory CD8+ t cell homeostasis. J. Exp. Med. 200 (2004), 825–834.
25. Fyfe, G.A., Fisher, R.I., Rosenberg, S.A., et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14 (1996), 2410–2411.
26. Klapper, J.A., Downey, S.G., Smith, F.O., et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113 (2008), 293–301.
27. Rosenstein, M., Ettinghausen, S.E., Rosenberg, S.A., Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. 137 (1986), 1735–1742.
28. Anderson, T.D., Hayes, T.J., Gately, M.K., et al. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab. Invest. 59 (1988), 598–612.
29. Ahmadzadeh, M., Rosenberg, S.A., IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006), 2409–2414.
30. Grabstein, K.H., Eisenman, J., Shanebeck, K., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264 (1994), 965–968.
31. Berard, M., Brandt, K., Bulfone-Paus, S., et al. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol. 170 (2003), 5018–5026.
32. Marks-Konczalik, J., Dubois, S., Losi, J.M., et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 11445–11450.
33. Waldmann, T.A., Lugli, E., Roederer, M., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117 (2011), 4787–4795.
34. Berger, C., Berger, M., Hackman, R.C., et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114 (2009), 2417–2426.
35. Anderson, D.M., Kumaki, S., Ahdieh, M., et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J. Biol. Chem. 270 (1995), 29862–29869.
36. Giri, J.G., Kumaki, S., Ahdieh, M., et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14 (1995), 3654–3663.
37. Woo, S.R., Fuertes, M.B., Corrales, L., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
38. Zhang, X., Sun, S., Hwang, I., et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8 (1998), 591–599.
39. Sneller, M.C., Kopp, W.C., Engelke, K.J., et al. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood 118 (2011), 6845–6848.
40. Lugli, E., Goldman, C.K., Perera, L.P., et al. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 116 (2010), 3238–3248.
41. Picker, L.J., Reed-Inderbitzin, E.F., Hagen, S.I., et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Invest 116 (2006), 1514–1524.
42. Conlon, K.C., Lugli, E., Welles, H.C., et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33 (2015), 74–82.
43. Takeshita, T., Asao, H., Ohtani, K., et al. Cloning of the gamma chain of the human IL-2 receptor. Science 257 (1992), 379–382.
44. Tang, F., Zhao, L.T., Jiang, Y., et al. Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol. Immunol. 5 (2008), 189–196.
45. Klebanoff, C.A., Finkelstein, S.E., Surman, D.R., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 1969–1974.
46. Kobayashi, H., Dubois, S., Sato, N., et al. The role of trans-cellular IL-15-presentation in the activation of NK-mediated killing, which leads to enhanced tumor immunesurveillance. Blood 105 (2005), 721–727.
47. Yu, P., Steel, J.C., Zhang, M., et al. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin. Cancer Res. 16 (2010), 6019–6028.
48. Anthony, S.M., Schluns, K.S., Emerging roles for IL-15 in the activation and function of T cells during immune stimulation. Res. Rep. Biol. 6 (2015), 25–37.
49. Fehniger, T.A., Suzuki, K., Ponnappan, A., et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193 (2001), 219–231.
50. Eisenman, J., Ahdieh, M., Beers, C., et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20 (2002), 121–129.
51. Mortier, E., Quemener, A., Vusio, P., et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281 (2006), 1612–1619.
52. Bergamaschi, C., Bear, J., Rosati, M., et al. Circulating interleukin-15 (IL-15) exists as heterodimeric complex with soluble IL-15 receptor alpha (IL-15Ralpha) in human serum. Blood 120 (2012), 1–8.
53. Chertova, E., Bergamaschi, C., Chertov, O., et al. Characterization and favorable in vivo properties of heterodimeric soluble IL-15. IL-15Ralpha cytokine compared to IL-15 monomer. J. Biol. Chem. 288 (2013), 18093–18103.
54. Watson, D.C., Bayik, D., Srivatsan, A., et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials 105 (2016), 195–205.
55. Dubois, S., Patel, H.J., Zhang, M., et al. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J. Immunol. 180 (2008), 2099–2106.
56. Czajkowsky, D.M., Hu, J., Shao, Z., et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med. 4 (2012), 1015–1028.
57. Elpek, K.G., Rubinstein, M.P., Bellemare-Pelletier, A., et al. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 21647–21652.
58. Epardaud, M., Elpek, K.G., Rubinstein, M.P., et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68 (2008), 2972–2983.
59. Bessard, A., Sole, V., Bouchaud, G., et al. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol. Cancer Ther. 8 (2009), 2736–2745.
60. Xu, W., Jones, M., Liu, B., et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73 (2013), 3075–3086.
61. Kim, P.S., Kwilas, A.R., Xu, W., et al. IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget 7 (2016), 16130–16145.
62. Mathios, D., Park, C.K., Marcus, W.D., et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int. J. Cancer 138 (2016), 187–194.
63. Rhode, P.R., Egan, J.O., Xu, W., et al. Comparison of the superagonist complex ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4 (2016), 49–60.
64. Gomes-Giacoia, E., Miyake, M., Goodison, S., et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One, 9, 2014, e96705-.
65. Felices, M., Chu, S., Kodal, B., et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol. Oncol. 145 (2007), 453–461.
66. Bailey, C.P., Budak-Alpdogan, T., Sauter, C.T., et al. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity. Oncotarget 8 (2017), 44366–44378.
67. Desbois, M., Le, V.P., Coutzac, C., et al. IL-15 trans-Signaling with the superagonist RLI promotes Effector/Memory CD8+ t cell responses and enhances antitumor activity of PD-1 antagonists. J. Immunol. 197 (2016), 168–178.
68. Evans, R., Fuller, J.A., Christianson, G., et al. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell. Immunol. 179 (1997), 66–73.
69. Chapoval, A.I., Fuller, J.A., Kremlev, S.G., et al. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. 161 (1998), 6977–6984.
70. Sun, H., Liu, D., IL-15/sIL-15Ralpha gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys. Cancer Gene Ther. 23 (2016), 54–60.
71. McInnes, I.B., Leung, B.P., Sturrock, R.D., et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 3 (1997), 189–195.
72. Carson, W.E., Ross, M.E., Baiocchi, R.A., et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J. Clin. Invest. 96 (1995), 2578–2582.
73. Cao, S., Troutt, A.B., Rustum, Y.M., Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res. 58 (1998), 1695–1699.
74. Suzuki, E., Kapoor, V., Jassar, A.S., et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11 (2005), 6713–6721.
75. Ko, H.J., Kim, Y.J., Kim, Y.S., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67 (2007), 7477–7486.
76. Yu, P., Steel, J.C., Zhang, M., et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 6187–6192.
77. Dubois, S.P., Waldmann, T.A., Muller, J.R., Survival adjustment of mature dendritic cells by IL-15. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8662–8667.
78. Zhang, M., Yao, Z., Dubois, S., et al. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 7513–7518.
79. Zhang, M., Ju, W., Yao, Z., et al. Augmented IL-15Ralpha expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J. Immunol. 188 (2012), 6156–6164.
80. Ochoa, M.C., Fioravanti, J., Rodriguez, I., et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 73 (2013), 139–149.
81. Vincent, M., Bessard, A., Cochonneau, D., et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int. J. Cancer 133 (2013), 757–765.
82. Kermer, V., Hornig, N., Harder, M., et al. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy. Mol. Cancer Ther. 13 (2014), 112–121.
83. Laprevotte, E., Voisin, G., Ysebaert, L., et al. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J. Immunol. 191 (2013), 3634–3640.
84. Vincent, M., Teppaz, G., Lajoie, L., et al. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs 6 (2014), 1026–1037.
85. Liu, B., Kong, L., Han, K., et al. A novel fusion of ALT-803 (Interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses. J. Biol. Chem. 291 (2016), 23869–23881.
86. Rosario, M., Liu, B., Kong, L., et al. The IL-15-Based ALT-803 complex enhances fcgammaRIIIa-Triggered NK cell responses and In vivo clearance of B cell lymphomas. Clin. Cancer Res. 22 (2016), 596–608.
87. Huang, J., Schisler, J., Wong, H.C., et al. Intravesical ALT-803 for BCG-unresponsive bladder cancer – a case report. Urol. Case Rep. 14 (2017), 15–17.
88. Bamford, R.N., Battiata, A.P., Burton, J.D., et al. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 2897–2902.
89. Dobbeling, U., Dummer, R., Laine, E., et al. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 92 (1998), 252–258.
90. Villinger, F., Miller, R., Mori, K., et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 22 (2004), 3510–3521.
91. Mueller, Y.M., Petrovas, C., Bojczuk, P.M., et al. Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques. J. Virol. 79 (2005), 4877–4885.